BMJ Open

Risk factors, symptom reporting, healthcare-seeking behaviour and adherence to public health guidance: protocol for Virus Watch, a prospective community cohort study

Andrew Hayward,[1] Ellen Fragaszy,[2,3] Jana Kovar,[1] Vincent Nguyen,[1,2] Sarah Beale,[1,2] Thomas Byrne,[2] Anna Aryee,[2] Pia Hardelid [ID] ,[4] Linda Wijlaars [ID] ,[5,6] Wing Lam Erica Fong,[2] Cyril Geismar,[1,2] Parth Patel,[2] Madhumita Shrotri,[2] Annalan M D Navaratnam,[1,2] Eleni Nastouli,[5,7] Moira Spyer,[5,7] Ben Killingley,[8,9] Ingemar Cox,[10] Vasileios Lampos,[10] Rachel A McKendry,[11] Yunzhe Liu,[12] Tao Cheng,[12] Anne M Johnson,[13] Susan Michie,[14] Jo Gibbs,[13] Richard Gilson,[13] Alison Rodger,[13,15] Robert W Aldridge [ID] [2]

For numbered affiliations see end of article.

Correspondence to
Dr Andrew Hayward;
a.hayward@ucl.ac.uk

ABSTRACT

Introduction The coronavirus (COVID-19) pandemic has caused significant global mortality and impacted lives around the world. Virus Watch aims to provide evidence on which public health approaches are most likely to be effective in reducing transmission and impact of the virus, and will investigate community incidence, symptom profiles and transmission of COVID-19 in relation to population movement and behaviours.

Methods and analysis Virus Watch is a household community cohort study of acute respiratory infections in England and Wales and will run from June 2020 to August 2021. The study aims to recruit 50 000 people, including 12 500 from minority ethnic backgrounds, for an online survey cohort and monthly antibody testing using home fingerprick test kits. Nested within this larger study will be a subcohort of 10 000 individuals, including 3000 people from minority ethnic backgrounds. This cohort of 10 000 people will have full blood serology taken between October 2020 and January 2021 and repeat serology between May 2021 and August 2021. Participants will also post self-administered nasal swabs for PCR assays of SARS-CoV-2 and will follow one of three different PCR testing schedules based on symptoms.

Ethics and dissemination This study has been approved by the Hampstead National Health Service (NHS) Health Research Authority Ethics Committee (ethics approval number 20/HRA/2320). We are monitoring participant queries and using these to refine methodology where necessary, and are providing summaries and policy briefings of our preliminary findings to inform public health action by working through our partnerships with our study advisory group, Public Health England, NHS and government scientific advisory panels.

INTRODUCTION

The COVID-19 pandemic has caused millions of deaths and impacted lives around the world with the closure of schools, workplaces

Strengths and limitations of this study

► Virus Watch is a large national household community cohort study of the occurrence of and risk factors for COVID-19 infection that aims to recruit 50 000 people, including 12 500 from minority ethnic backgrounds.

► Virus Watch is designed to estimate the incidence of PCR-confirmed COVID-19 in those with respiratory and non-respiratory presentations and the incidence of hospitalisation among PCR-confirmed COVID-19 cases.

► Virus Watch will measure effectiveness and impact of recommended COVID-19 control measures including testing, isolation, respiratory and hand hygiene measures, and social distancing on risk of respiratory infection.

► Only households with a lead householder able to speak English are able to take part in the study. Participant information sheets and consent forms are available in 9 languages but the study surveys are in English, limiting participation for non-English speaking households.

► Only households of up to six people were eligible for inclusion and they are also required to have access to an internet connection. These restrictions will limit the generalisability to large or multigenerational households, and those without access to the internet.

and limitations on freedom of movement. Vaccines and effective scalable treatments for COVID-19 have been developed and while these are rolled out across England and Wales we will need to rely on other measures to stop the spread of COVID-19. We will also require

studies to examine their long-term effectiveness as they are implemented across England and Wales.

Governments, including those of the UK devolved nations, are adopting a wide range of control measures to limit the spread of infection. These include isolation of people with COVID-19 symptoms and their household contacts, widespread testing and contact tracing, digital contact tracing using mobile phone apps, broad social distancing measures and local control measures. Environmental cleaning, hand hygiene and face mask use are also advised.

Much of our current knowledge of COVID-19 comes from observations at the more severe end of the disease spectrum, in hospitalised patients and individuals who die having tested positive for the disease.[1–3] Although large-scale studies of prevalence of PCR positive infection and seroprevalence have been established, there is currently limited information on symptom profiles through the course of illness in non-hospitalised populations, children, social and behavioural risk factors for infection, strength and duration of immunity, household and community transmission risk, and population behaviours during periods of wellness and illness (including social contacts, use of public spaces, testing behaviours, isolation, mask use, hand and respiratory hygiene). This information can only be gathered accurately through prospective large-scale community cohorts. Our experience of the Medical Research Council (MRC)/Wellcome Flu Watch study[4 5] and the Economic and Social Research Council (ESRC) Bug Watch[6] study has allowed us to rapidly establish a national household cohort study of 50 000 individuals.

Virus Watch aims to provide evidence on which public health approaches are most likely to be effective in reducing the spread and impact of the virus and will investigate community incidence, symptom profiles and transmission of COVID-19 in relation to population movement and behaviour.

METHODS AND ANALYSIS
Study design and setting

Virus Watch is a household community cohort study of acute respiratory infections in England and Wales covering the second and potential subsequent waves of the COVID-19 pandemic. The study period will be from 1 June 2020 to 31 August 2021. The study aims to recruit 50 000 individuals, including 12 500 from minority ethnic backgrounds for an online survey cohort (study 1). Nested within this larger study will be a subcohort of 10 000 individuals (study 2), including 3000 people from minority ethnic backgrounds. Participants in this laboratory subcohort will be selected based on their geographical distance from one of our blood-taking clinics; either a 10 km radius from a clinic in cities or a 20 km radius in rural areas. Participants will be balanced to be representative of the UK population for sex, age and region. Figure 1 provides an overview of the study design.

Households self-select into the study if they live in England or Wales and all members of a household need to consent to take part in the study to meet our inclusion criteria (online supplemental appendix 1). Households need to have an internet connection on a phone, tablet or computer, email, and at least one adult household member that can read English.A household is defined as one or more people (not necessarily related) whose usual residence (4 days/week or more) is at the same address. These householders share cooking facilities, a living room or sitting room or dining area.


Figure 1 Overview of cohort recruitment, PCR swabbing schedules and data collection for the Virus Watch household community cohort study.

Primary outcomes

Study 1: online survey cohort

1. Incidence of respiratory infection symptoms, including COVID-19 disease case definitions.
2. Effectiveness and impact of recommended COVID-19 control measures including testing, isolation, social distancing, respiratory and hand hygiene measures on risk of respiratory infection.
3. Frequency of adherence to public health recommendations for these control measures.
4. Proportion of community infections that result in hospital admissions and death.
5. Vaccine effectiveness against asymptomatic and symptomatic infections.

Study 2: laboratory testing subcohort

1. Incidence of PCR-confirmed COVID-19.
2. Incidence of PCR-confirmed COVID-19 in those with non-respiratory presentations.
3. Incidence of hospitalisation among PCR-confirmed COVID-19 cases.
4. Proportion of individuals with SARS-CoV-2 antibodies acquired through natural infection to pandemic coronavirus.
5. Proportion of individuals with cross-reacting antibodies to seasonal coronaviruses acquiring (or not) SARS-CoV-2.
6. Household secondary attack rates.
7. Protective effect of antibodies on infection and re-infection as well as the severity and spectrum of presentation.

Recruitment

We will use the Royal Mail Post Office Address File to generate a list of residential address lists from which households can be sampled and sent Virus Watch recruitment postcards to. The proposed initial sample design is a single-stage stratified probability sample where implicit stratification is employed to benefit from the precision gains that stratified sampling can bring. Within each region, residential addresses are sorted by (A) quintiles of Index of Multiple Deprivation 2019, (B) within quintiles by local authorities, (C) postcodes, and (D) address. We will perform this in the nine government office regions of England as well as Wales (10 study regions in total).

We will assess recruitment rates and the representativeness of this initial sample following the mail out of 50 000 postcards. If recruitment is lower than expected or under-representative of the national population, we will redesign our recruitment campaign to include a range of methods in order to build the cohort. This mixed recruitment strategy will be flexible and use a variety of methods including social media, study leaflet drops, text messaging, personalised letters and incentives. Social media adverts will be used to inform individuals about the study and direct them to our website, http://ucl-virus-watch.net/, where they can read the participant information sheets and consent to taking part. Digital invitations will also be created for sharing via WhatsApp. Text messages and postal letters inviting patients from their general practitioner (GP) clinics will be organised via Local Clinical Research Networks.[7] We will also work with trusted community partners and religious organisations to promote recruitment into the study.

In order for a household to be enrolled, they will require an internet connection (Wi-Fi, fixed or on a mobile phone), email address, and all household members must agree to take part. Households will nominate a lead householder who will submit study questionnaires. The lead householder will need to be able to read English to support other household members in survey completion. A household is defined as one or more people (not necessarily related) whose usual residence (4 days/week or more) is at the same address. These householders share cooking facilities, and may share a living room or sitting room or dining area if available. Households with more than six members will not be eligible for the study—this criterion was set due to limitations of the Research Electronic Data Capture (REDCap) survey infrastructure which did not function correctly when attempting to work with household sizes of greater than six during our pilot testing of the survey.

Virus Watch is powered for our primary aims in study 2 and the estimation of population-level symptomatic COVID-19 attack rate over time. Recruiting a cohort that is representative of the population is time consuming as it requires an initial invitation into a study followed by multiple follow-up contacts encouraging invited individuals to register. Given the urgency of the public health situation to roll out our study as quickly as possible, we chose a different approach whereby we recruit a large cohort of 50 000 individuals and from within that cohort we select a subsample for the testing cohort (subcohort 1) which is representative of the population in terms of age, sex, ethnicity, region, household size and proportion of households with children. The larger cohort will be important in assessing rates and predictors of less frequent outcomes such as hospitalisation and death. Given recent information of marked ethnicity differences in mortality rates from COVID-19, we also chose to recruit an ethnicity sample designed to be sufficiently large to provide early indicators of whether these differential mortality rates are due to differences in disease incidence or in differences in severity or both.

Power analysis

The testing subcohort is powered for accurate weekly age-specific disease incidence rates to be measured assuming 20%–30% clinical attack rate over 18 weeks. With a clinical attack rate of 30% of whom 20% need hospitalisation and 0.5% die, we expect the following number of outcome events in our testing cohort of 10 000 individuals in study 2: 3000 COVID-19 illnesses, 600 hospitalised cases and 15 deaths. At 1 month into the outbreak we would be able to detect a 1.7-fold greater risk of disease in a population subgroup that constitutes one-fifth of the population, and

by 2 months the detectable relative risk would be only 1.2. At 1 month we could detect a 4% hospital admission rate among cases with 95% CI of 0.5 to 6.8, and by 2 months the CIs would narrow to 3.1 to 4.1. We have used estimates of the expected number of events over time to provide an indication of the fact that the cohort is sufficiently large to provide valuable information through the course of the pandemic. Sample size calculations have been informed by a realistic assessment of what we can achieve based on our previous experience.[4 6] For the serology cohort of 3000 people from minority ethnic backgrounds we assume a modest design effect due to household and geographical clustering, and 500 participants for six different minority ethnic backgrounds would enable the measurement of a cumulative incidence of 10% with 95% CIs of 3% by each minority ethnic group.

Participant materials and incentives

Participant information sheets will be held on our study website (these along with consent forms were translated into six languages and a further three languages were added from December 2020). In order to participate, the whole household must take part. Each adult participant will need to read through study information, and provide online informed consent for themselves and any children they are legally responsible for. Children aged 6–9 and 10–15 years, respectively, will also be asked to read through age-specific study participant information sheets and provide online informed assent. For children aged 5 and under, parents/guardians will consent on their behalf. Informed consent data will be securely stored in the University College London (UCL) Data Safe Haven which has been certified to the ISO27001 information security standard and conforms to the National Health Service (NHS) Digital's Data Security and Protection Toolkit. Local study teams will reconsent participants face to face, prior to undertaking blood sampling, and adult participants in study 2 will be offered a £10 voucher to reimburse travel costs, if required. From February 2021, invitation letters sent by GP clinics will include a £20 voucher for households who agree to take part in the study.

Data collection and follow-up
Study 1: online survey cohort

The online survey cohort will collect data and follow up participants through six different sources. Survey data will be collected using REDCap electronic data capture tools hosted on the UCL Data Safe Haven (online supplemental appendices 2–4).[8] REDCap is a secure, web-based application for research studies. The UCL Data Safe Haven provides a technical solution for storing, handling and analysing identifiable data. It has been certified to the ISO27001 information security standard and conforms to NHS Digital's Data Security and Protection Toolkit .

1. Baseline survey. The lead householder will be asked to complete an online baseline survey for each member of their household. Information collected includes: demographics, occupation, income, ethnicity, country of birth, year of entry to UK, chronic medical conditions, medications, pregnancy status, vaccines, mode of transport to work, any previous contact with someone with COVID-19, previous symptoms of COVID-19-like illness and infection prevention behaviours such as social distancing and hand hygiene.

2. Illness surveys. Participants will be followed up weekly via an email with a link to an illness survey. This is a weekly survey of the presence or absence of symptoms that could indicate COVID-19 disease including respiratory, general infection or gastrointestinal symptoms. During illness, prospective daily symptom recording, quality of life, health-seeking behaviour (NHS 111, GP in person, GP by phone, accident and emergency, pharmacy, hospital), treatments and NHS investigations will be recorded. This survey will also include any respiratory and hand hygiene measures, self-isolation, activities and social contact, travel and face mask use. Questions around behavioural interventions, such as mask wearing and social distancing, aim to reflect the context and frequency/degree to which behaviours are practised according to governmental and public health guidelines and relevant scientific literature. The survey includes questions to the household on activities undertaken in the week prior to symptom onset. The weekly survey will also be used to capture test results received from outside the study and requests to self-isolate, for example, via the UK Test-Trace-Isolate system. The weekly survey will also ask about participants' COVID-19 vaccination uptake, including their date of vaccination, dose (ie, first or second) and which vaccine was administered.

3. Monthly surveys. A number of questions will be asked every month. The monthly surveys also provide flexibility to ask additional questions (eg, behavioural changes) to reflect any new government directives on social distancing, testing, contact tracing and vaccine delivery. Core questions will also allow us to follow up reasons for any non-response in a given month (eg, because of illness, hospitalisation or holiday). We will also ask about online health information seeking, social distancing, including recent (week before) contacts, activities, places visited and hand and respiratory hygiene. As with the weekly questionnaire, questions around behavioural practices will reflect governmental and public health guidelines and the scientific literature; monthly questionnaires will also investigate barriers and enablers to health-related behaviours using purpose-developed questionnaires based on the Capability, Opportunity, Motivation, Behaviour model. We will also ask about finances, employment and mental health to see how the COVID-19 response is affecting participants' well-being and ability to work. We will ask about access to healthcare for non-COVID-19 health problems to explore the indirect health impacts of the pandemic. We will ask about any COVID-19 PCR or antibody test results performed outside the study and not

already reported through baseline surveys. We will ask about influenza vaccine uptake and COVID-19 vaccination intentions.

4. Data linkage. NHS Digital will undertake quarterly data linkage between cohort 1 and Hospital Episode Statistics (HES), which includes admitted patient and critical care episodes, outpatient department bookings and emergency care contacts. This linkage will also include Office for National Statistics mortality data, COVID-19 vaccination records and virology testing data routinely collected by Public Health England (PHE), Public Health Wales and the Department of Health and Social Care through 'Pillar 1' (testing in hospital patients and health and care workers) and 'Pillar 2' (community testing). These data sources will be linked to the cohort using name, NHS numbers, dates of birth and postal address. Identifying variables will be removed before the linked data are transferred back to UCL for analysis. These data linkages will continue for up to 5 years after the end of the study as we anticipate COVID-19 will become a recurring winter infection and we wish to understand its impact on health services in subsequent years. These linkage studies will identify any participants who have been admitted to hospital or died due to causes that could be directly or indirectly linked to the COVID-19 pandemic. Indirect causes include those related to limitations in healthcare access during the pandemic. Reductions in the use of routine health services will also be monitored via linkage to HES data.

5. Geolocation tracking. All adult participants will be asked about optional consent to use a secure geolocation tracking app (Tracker for ArcGIS) installed on their mobile phone for the duration of the study.

6. Monthly antibody testing using home fingerprick kits. Adults aged 18 years and over enrolled in the online survey cohort, with the exception of those in laboratory testing subcohort group 3, will be offered monthly antibody testing starting February 2021 and continuing until the end of the study, using home fingerprick kits for self-collection of capillary blood samples. Those aged under 18 and living with adults enrolled in monthly antibody testing will continue completing online surveys. Monthly antibody testing (February–August 2021) will use Conformitè Eurōpĕenne (CE)-marked at-home fingerprick kits designed to collect small-volume (400–600 μL) capillary blood samples. Samples are self-collected by adult participants and returned to a United Kindom Accreditation Service (UKAS)-accredited laboratory via prepaid post, where they will be tested for anti-nucleocapsid and anti-spike antibodies using validated electrochemiluminescence immunoassays.

Study 2: laboratory testing subcohort

All participants agreeing to take part in the main cohort (study 1) will be asked to provide consent to be contacted and invited to participate in one of the three laboratory testing subgroups. This will enable a cohort of 10 000 individuals selected from the main cohort of 50 000 individuals to be maximally representative of the population of England and Wales. All participants taking part in study 2 will be asked to use the national test, trace and isolation system in addition to providing samples as part of Virus Watch.

Study 2 will consist of three groups that will follow different schedules of antibody testing and nasal/throat swabs for PCR testing.

Group 1 (n=7000)

With data from this group we aim to identify infection in those with a wide range of respiratory symptoms. Participants will be asked to submit a nose/throat swab if they experience 2 consecutive days of: fever (>37.8°C), feeling feverish, or new persistent cough, or loss or altered sense of smell or taste (COVID-19 suspected case definition), or shortness of breath, or ear pain or change in hearing, or sore throat, or sneezing, or blocked nose, or runny nose, or wheeze or sinus pain or congestion (other respiratory manifestations).

Group 2 (n=1000)

This group aims to identify the importance of non-respiratory presentations. Participants will be asked to submit a self-taken nasal/throat swab for PCR identification of COVID-19 and other respiratory viruses if:

► Either 2 consecutive days of respiratory symptoms (eg, cough, runny nose, sneezing, shortness of breath, sore throat, blocked nose, sinus pain or congestion, ear pain or change in hearing, wheezing, loss of or altered sense of taste or sense of smell).

► Or 2 consecutive days of gastrointestinal symptoms (eg, diarrhoea/loose stools, abdominal pain, nausea or vomiting, loss of appetite).

► Or 2 consecutive days of general infection symptoms (eg, feeling feverish, having a high temperature, feelings of severe unexplained tiredness, generalised muscle or joint aches).

Group 3 (n=2000)

This group aims to identify the extent of household transmission. Participants will be asked to submit a nose/throat swab if they experience 2 consecutive days of cough or fever or loss of sense of taste or smell. Household contacts of the index case will also be asked to submit a swab on the same day whether or not they have symptoms.

If any of the swabs indicate SARS-CoV-2 infection, all household members will be asked to repeat the swab on day 7 and day 14. If there are no new SARS-CoV-2 cases in the household arising from swabs on days 7 and 14 (assumed secondary cases) then all household members will be asked to undertake a home fingerprick antibody test on day 21. If there is one or more secondary cases in the household then the entire household will be asked to take an additional swab on day 21 and then undertake the fingerprick antibody tests on day 28.

End of follow-up

Online participant follow-up will end in August 2021 for households enrolled in monthly antibody testing, and in May 2021 for others, although depending on the progression of COVID-19, we may ask participants to continue in the study for longer. Participants will be sent an exit survey. Participants will be contacted to arrange a second blood sample collection from April 2021. Follow-up through data linkage with HES, COVID-19 vaccination records and mortality data will continue for 5 years after the end of the study.

Laboratory testing
Antibody testing

Study 2 will be using two different types of antibody tests. First, full blood serology will be taken between October 2020 and January 2021. We will use experienced healthcare professionals, including research nurses from the National Institute for Health Research Clinical Research Networks.[7] Depending on local circumstances, visits to participants' homes to take blood may also be arranged. Children aged 15 years or less can opt out of having their blood taken but will be offered a fingerprick antibody test conducted by a healthcare worker instead. All participants from laboratory group 3 will additionally be offered a fingerprick antibody test at the same time as blood taking. From April 2021 until July 2021, we will invite all participants back for full blood tests or, for children who do not wish to have a full bleed, healthcare worker-delivered fingerprick-based antibody tests.

Families of children who have not been able to attend for a blood test, or for a healthcare worker-delivered fingerprick antibody test, will be provided with postal kits to perform these at home. We also plan to use fingerprick antibody testing where local clinics are no longer able to undertake full blood tests due to COVID-19 travel restrictions. Extremely clinically vulnerable participants will be sent home fingerprick tests instead of being asked to provide a serological sample.

Virus detection

Participants will post swab samples for PCR assays of SARS-CoV-2, and subsequent testing for influenza virus, seasonal coronavirus, rhinovirus and respiratory syncytial virus. When SARS-CoV-2 is identified we will also undertake whole-genome sequencing of the virus. Samples for COVID-19 diagnostics will be handled and processed according to the NHS and UCL guidance on sample handling during the COVID-19 pandemic.

COVID-19 PCR and serology results will be returned to participants via email message systems. These messages will include links to official support, information and advice from NHS and PHE as well as advice on how to interpret results based on current evidence. In laboratory group 3, where positive test results will trigger further testing of the household, the results email will also include details explaining the additional testing requests. We will be not asking for inconclusive PCR results to be repeated

Statistical analysis

Our primary analyses during the winter 2020/2021 season will focus on estimating age-specific weekly rates of symptoms and risk factors for PCR-confirmed COVID-19 illness and hospitalisation. For these analyses we will use Poisson regression models that account for clustering by household using robust SEs and we will explore the use of stratification or weighting of the sample by age and region as necessary to give nationally representative estimates. Weekly rates will be expressed per 100 000 person-weeks for ease of comparison with national surveillance data.

We will examine the proportion of the population infected during the first wave (eg, February–September 2020) and second and potential future pandemic waves. We will estimate the percentage of the population infected by calculating age and wave-specific rates of serological infection and PCR-confirmed disease per 100 person-seasons using Poisson regression with robust SEs to account for household-level clustering. A person-season will be defined by the epidemic curve in the cohort and therefore rates will account for differential follow-up time during each epidemic peak. In these analyses we will examine risk factors for infection, disease, disease severity and disease transmission.

We will estimate the proportion of serologically confirmed SARS-CoV-2 infections leading to symptomatic disease. First, we will calculate age-adjusted attributable rates of illness due to infection (subtracting rates of respiratory illness in non-seroconverters from those in seroconverters). Second, we will measure the proportion of seroconverters with PCR-confirmed COVID-19. Analyses plans will be developed prior to conducting all analyses.

We will estimate vaccine effectiveness against asymptomatic SARS-CoV-2 infections and against symptomatic COVID-19 using anti-nucleocapsid seroconversion, positive PCR testing and self-reported symptom data. We will use both time-to-event and test-negative analytical frameworks. Using quantitative antibody data, we will assess the dynamics of anti-spike antibodies over time and the relationship between antibody titres and the risk of infection.

While the study is being conducted, we will produce early, preliminary results and analyses for participants, the general public, government scientific advisory groups and policymakers in order to inform the public health response to the pandemic. These analyses will be reactive to the epidemiological circumstances and are therefore not defined in this protocol.

Modelling

We will build on our experience of working with PHE, Google and Microsoft to use anonymous national or subnational aggregate web search engine data[9 10] to monitor the spreading of the disease. We will use our study data as ground truth to train real-time disease prevalence estimation algorithms. We will annotate Global Positioning System tracking data into standard categories including time at work and home, social venues, supermarkets,

hospitals, GPs and transport mode for incorporation in classical epidemiological analyses. Integrating the linked survey data, we will develop a predictive spatiotemporal transmission model to investigate the impact of various social distancing strategies.

Missing data

We have several strategies that attempt to address the issue of missing data. First, we have sought to minimise the amount and impact of missing data for key outcomes and exposures through the study design. For example, for a number of our primary outcomes (PCR-confirmed illness, hospitalisation and death) and exposures (vaccination) we collect data both as self-reported and through data linkage with the relevant national data sets and registries. Second, we sought to minimise missing serological and Virus Watch specific swabbing outcomes in adults by making willingness to provide relevant specimens a prerequisite to study registration. Third, we know from our experience of previous community cohort studies of acute infections (Flu Watch[4] and Bug Watch[6]) that response to weekly surveys (where our symptom data are collected) is high at around 75%, which we believe is achieved by keeping these weekly data collections simple and quick to complete. We have aimed to replicate this approach in Virus Watch. Fourth, for important missing baseline demographic data (eg, age and sex) we have created follow-up surveys to try and collect missing data at a later point in time. Fifth, where necessary, we will address missing data in our analyses and use multiple imputation methods if appropriate.

Patient and public involvement

Due to the urgent nature of this study, we did not involve participants in its original design. We have previously conducted patient and public involvement to support similar community cohort studies of acute infections using similar methodologies. We have engaged the Young Persons Advisory Group for research at Great Ormond Street Hospital to provide feedback on our Children's Participant Information Sheets. We have worked with the Race Equality Foundation and Doctors of the World in advising on the inclusion of people from minority ethnic backgrounds in Virus Watch and have set up an advisory group to inform the ongoing design and dissemination of health equity aspects of Virus Watch. They were not asked to assess the burden of the intervention and time required to participate in the research due to the urgent nature of setting the study up. This advisory group (consisting of lay members of the public, community leaders, charities and policy organisations who will be reimbursed for their time) will guide our health equity analyses and steer us on their implications for people, communities and policy. The advisory group will also help us prioritise what information and results to share, when and in what format.

ETHICS AND DISSEMINATION

This is a national study that has been approved by the Hampstead NHS Health Research Authority Ethics Committee (ethics approval number 20/HRA/2320). The study is compliant with the requirements of General Data Protection Regulation (2016/679) and the Data Protection Act (2018). All investigators and study site staff will comply with the requirements of the General Data Protection Regulation (2016/679) with regard to the collection, storage, processing and disclosure of personal information, and will uphold the Act's core principles.

We will provide opportunities for survey participants to comment on survey methodology in the first monthly survey and consider revisions based on this. We are also monitoring participant queries through our study email address and using these to refine methodology where necessary.

Data sharing and access

We aim to share aggregate data from this project on our website and via a 'Findings so far' section on our website—https://ucl-virus-watch.net/. We will also be sharing individual record-level data with personal identifiers removed on a research data-sharing service such as the Office for National Statistics Secure Research Service.[11] In sharing the data we will work within the principles set out in the UK Research and Innovation (UKRI) guidance on best practice in the management of research data.[12] Access to use of the data while research is being conducted will be managed by the chief investigators (AH and RWA) in accordance with the principles set out in the UKRI guidance on best practice in the management of research data. It is the intention that the data arising from this research will initially be collected, cleaned and validated by the UCL research team and once this has been completed will be shared for wider use. We aim to make subsets of the data more rapidly available both on our study website and via the public-facing dashboard during the ongoing phase of data collection. In line with Principle 5 of the UKRI guidance on best practice in the management of research data, we plan to release data in batches as they become available or as updated results are published. Individual record data linked using NHS Digital will not be shared, only aggregated results. HES and mortality data may be obtained from a third party and are not publicly available. These data are owned by a third party and can be accessed by researchers applying to the Health and Social Care Information Centre for England. We will put analysis code on publicly available repositories to enable their reuse.

Author affiliations
[1]Institute of Epidemiology and Health Care, University College London, London, UK
[2]Centre for Public Health Data Science, Institute of Health Informatics, University College London, London, UK
[3]Department of Infectious Disease Epidemiology, LSHTM, London, UK
[4]Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK
[5]Population, Policy and Practice, University College London, London, UK

[6]Primary Care and Population Health, University College London, London, UK
[7]Francis Crick Institute, London, UK
[8]University of Nottingham School of Medicine, Nottingham, UK
[9]University College London Hospital, London, UK
[10]Department of Computer Science, University College London, London, UK
[11]London Centre for Nanotechnology and Division of Medicine, University College London, London, UK
[12]SpaceTimeLab, Department of Civil, Environmental and Geomatic Engineering, University College London, London, UK
[13]Institute for Global Health, University College London, London, UK
[14]Centre for Behaviour Change, University College London, London, UK
[15]Royal Free London NHS Foundation Trust, London, UK

Twitter Linda Wijlaars @epi_counts, Eleni Nastouli @Eleni Nastouli and Robert W Aldridge @rob_aldridge

Contributors Conceptualisation: AH, EF, JK, PH, EN, BK, IC, VL, RAM, TC, AMJ, SM, JG, RG, AR, RWA. Investigation, methodology: all authors. Project administration: AH, EF, JK, VN, SB, TB, AA, PH, LW, WLEF, CG, PP, MSh, AMDN, EN, MSp, RWA. Writing– original draft preparation: all authors. Software: VN, TB, SB, RWA. Resources: AH, EF, JK, PH, EN, BK, IC, VL, RAM, TC, YL, AMJ, SM, JG, RG, AR, RWA. Writing–review and editing: all authors.

Competing interests AH serves on the UK New and Emerging Respiratory Virus Threats Advisory Group. AMJ was a governor of Wellcome Trust from 2011 to 2018 and is chair of the Committee for Strategic Coordination for Health of the Public Research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iDs
Pia Hardelid http://orcid.org/0000-0002-0154-1306
Linda Wijlaars http://orcid.org/0000-0003-1222-2922
Robert W Aldridge http://orcid.org/0000-0003-0542-0816

REFERENCES
1 Official UK coronavirus dashboard. Available: https://coronavirus. data.gov.uk/ [Accessed 30 Nov 2020].
2 Statistics. COVID-19 daily deaths. Available: https://www.england. nhs.uk/statistics/statistical-work-areas/covid-19-daily-deaths/ [Accessed 30 Nov 2020].
3 Coronavirus (COVID-19). Available: https://www.ons.gov.uk/peop lepopulationandcommunity/healthandsocialcare/conditionsanddis eases [Accessed 30 Nov 2020].
4 Fragaszy EB, Warren-Gash C, Wang L, *et al*. Cohort profile: the flu Watch study. *Int J Epidemiol* 2017;46:e18.
5 Hayward AC, Fragaszy EB, Bermingham A, *et al*. Comparative community burden and severity of seasonal and pandemic influenza: results of the flu Watch cohort study. *Lancet Respir Med* 2014;2:445–54.
6 Smith CM, Conolly A, Fuller C, *et al*. Symptom reporting, healthcare- seeking behaviour and antibiotic use for common infections: protocol for bug Watch, a prospective community cohort study. *BMJ Open* 2019;9:e028676.
7 Clinical Research Network. Available: https://www.nihr.ac.uk/explore- nihr/support/clinical-research-network.htm [Accessed 30 Nov 2020].
8 Harris PA, Taylor R, Thielke R, *et al*. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42:377–81.
9 Wagner M, Lampos V, Cox IJ, *et al*. The added value of online user- generated content in traditional methods for influenza surveillance. *Sci Rep* 2018;8:13963.
10 Lampos V, Majumder MS, Yom-Tov E. Tracking COVID-19 using online search, 2020. Available: http://arxiv.org/abs/2003.08086v10
11 Accessing secure research data as an accredited researcher. Available: https://www.ons.gov.uk/aboutus/whatwedo/statistics/ requestingstatistics/approvedresearcherscheme [Accessed 12 Mar 2021].
12 UKRI. Guidance on best practice in the management of research data. Available: https://www.ukri.org/wp-content/uploads/2020/10/ UKRI-020920-GuidanceBestPracticeManagementResearchData.pdf

Appendix 1 - Study inclusion and exclusion criteria:

Inclusion:

- Households self-select into the study.
- Participants need to join as a household (all must take part).
- They need to have internet connection on a phone, tablet or computer, email and at least one adult that can read English.

Exclusion Criteria

We will exclude participants if:

- Number of householders exceeds 6.
- Those without internet connection on a phone, tablet or computer, or an email address available to them as they will be unable to register
- There is no adult in the household who can read English (from March 2021 this will no longer be an exclusion criteria)
- A household is defined as one or more people (not necessarily related) whose usual residence (4days/week or more) is at the same address. These householders share
- cooking facilities, a living room or sitting room or dining area.

Confidential

Baseline for Lead Householder

Baseline Survey for [hh1_fname] [hh1_sname]

alive

_____

The baseline survey collects some basic information about each person participating in Virus Watch. We will ask about each household member in turn, please ask each adult to complete their own information and help children to complete their sections or complete them for them

[hh1_fname] [hh1_sname]: At birth you were described as?	○ Male ○ Female ○ Intersex ○ Prefer not to say
[hh1_fname] [hh1_sname]: Do you know your NHS Number? This can usually be found on an NHS letter	○ Yes ○ No
[hh1_fname] [hh1_sname]: What is your NHS Number?	_____
[hh1_fname] [hh1_sname]: Where is your place of Birth?	○ United Kingdom ○ Other
[hh1_fname] [hh1_sname]: When did you first come to live in the UK (approximately)? DD/MM/YYYY	_____

projectredcap.org

REDCap

Confidential

[hh1_fname] [hh1_sname]: Please specify where you were born:

- ◯ Afghanistan
- ◯ Albania
- ◯ Algeria
- ◯ American Samoa
- ◯ Andorra
- ◯ Angola
- ◯ Anguilla
- ◯ Antarctica
- ◯ Antigua And Barbuda
- ◯ Argentina
- ◯ Armenia
- ◯ Aruba
- ◯ Australia
- ◯ Austria
- ◯ Azerbaijan
- ◯ Bahamas
- ◯ Bahrain
- ◯ Bangladesh
- ◯ Barbados
- ◯ Belarus
- ◯ Belgium
- ◯ Belize
- ◯ Benin
- ◯ Bermuda
- ◯ Bhutan
- ◯ Bolivia
- ◯ Bosnia And Herzegovina
- ◯ Botswana
- ◯ Bouvet Island
- ◯ Brazil
- ◯ British Indian Ocean Territory
- ◯ Brunei Darussalam
- ◯ Bulgaria
- ◯ Burkina Faso
- ◯ Burundi
- ◯ Cambodia
- ◯ Cameroon
- ◯ Canada
- ◯ Cape Verde
- ◯ Cayman Islands
- ◯ Central African Republic
- ◯ Chad
- ◯ Chile
- ◯ China
- ◯ Christmas Island
- ◯ Cocos (keeling) Islands
- ◯ Colombia
- ◯ Comoros
- ◯ Congo
- ◯ Congo, The Democratic Republic Of The
- ◯ Cook Islands
- ◯ Costa Rica
- ◯ Cote D'ivoire
- ◯ Croatia
- ◯ Cuba
- ◯ Cyprus
- ◯ Czech Republic
- ◯ Denmark
- ◯ Djibouti
- ◯ Dominica
- ◯ Dominican Republic
- ◯ East Timor
- ◯ Ecuador
- ◯ Egypt
- ◯ El Salvador
- ◯ Equatorial Guinea
- ◯ Eritrea
- ◯ Estonia
- ◯ Ethiopia

projectredcap.org

REDCap

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

○ Falkland Islands (malvinas)
○ Faroe Islands
○ Fiji
○ Finland
○ France
○ French Guiana
○ French Polynesia
○ French Southern Territories
○ Gabon
○ Gambia
○ Georgia
○ Germany
○ Ghana
○ Gibraltar
○ Greece
○ Greenland
○ Grenada
○ Guadeloupe
○ Guam
○ Guatemala
○ Guinea
○ Guinea-bissau
○ Guyana
○ Haiti
○ Heard Island And Mcdonald Islands
○ Holy See (vatican City State)
○ Honduras
○ Hong Kong
○ Hungary
○ Iceland
○ India
○ Indonesia
○ Iran, Islamic Republic Of
○ Iraq
○ Ireland
○ Israel
○ Italy (Italian Republic)
○ Jamaica
○ Japan
○ Jordan
○ Kazakstan
○ Kenya
○ Kiribati
○ Korea, Democratic People's Republic Of
○ Korea, Republic Of
○ Kosovo
○ Kuwait
○ Kyrgyzstan
○ Lao People's Democratic Republic
○ Latvia
○ Lebanon
○ Lesotho
○ Liberia
○ Libyan Arab Jamahiriya
○ Liechtenstein
○ Lithuania
○ Luxembourg
○ Macau
○ Macedonia, The Former Yugoslav Republic Of
○ Madagascar
○ Malawi
○ Malaysia
○ Maldives
○ Mali
○ Malta
○ Marshall Islands
○ Martinique
○ Mauritania
○ Mauritius
○ Mayotte
○ Mexico

- ◯ Micronesia, Federated States Of
- ◯ Moldova, Republic Of
- ◯ Monaco
- ◯ Mongolia
- ◯ Montserrat
- ◯ Montenegro
- ◯ Morocco
- ◯ Mozambique
- ◯ Myanmar
- ◯ Namibia
- ◯ Nauru
- ◯ Nepal
- ◯ Netherlands
- ◯ Netherlands Antilles
- ◯ New Caledonia
- ◯ New Zealand
- ◯ Nicaragua
- ◯ Niger
- ◯ Nigeria
- ◯ Niue
- ◯ Norfolk Island
- ◯ Northern Mariana Islands
- ◯ Norway
- ◯ Oman
- ◯ Pakistan
- ◯ Palau
- ◯ Palestinian Territory, Occupied
- ◯ Panama
- ◯ Papua New Guinea
- ◯ Paraguay
- ◯ Peru
- ◯ Philippines
- ◯ Pitcairn
- ◯ Poland
- ◯ Portugal
- ◯ Puerto Rico
- ◯ Qatar
- ◯ Reunion
- ◯ Romania
- ◯ Russian Federation
- ◯ Rwanda
- ◯ Saint Helena
- ◯ Saint Kitts And Nevis
- ◯ Saint Lucia
- ◯ Saint Pierre And Miquelon
- ◯ Saint Vincent And The Grenadines
- ◯ Samoa
- ◯ San Marino
- ◯ Sao Tome And Principe
- ◯ Saudi Arabia
- ◯ Senegal
- ◯ Serbia
- ◯ Seychelles
- ◯ Sierra Leone
- ◯ Singapore
- ◯ Slovakia
- ◯ Slovenia
- ◯ Solomon Islands
- ◯ Somalia
- ◯ South Africa
- ◯ South Georgia And The South Sandwich Islands
- ◯ Spain
- ◯ Sri Lanka
- ◯ Sudan
- ◯ Suriname
- ◯ Svalbard And Jan Mayen
- ◯ Swaziland
- ◯ Sweden
- ◯ Switzerland
- ◯ Syrian Arab Republic
- ◯ Taiwan, Province Of China

○ Tajikistan
○ Tanzania, United Republic Of
○ Thailand
○ Togo
○ Tokelau
○ Tonga
○ Trinidad And Tobago
○ Tunisia
○ Turkey
○ Turkmenistan
○ Turks And Caicos Islands
○ Tuvalu
○ Uganda
○ Ukraine
○ United Arab Emirates
○ United Kingdom
○ United States
○ United States Minor Outlying Islands
○ Uruguay
○ Uzbekistan
○ Vanuatu
○ Venezuela
○ VietNam
○ Virgin Islands, British
○ Virgin Islands, U.s.
○ Wallis And Futuna
○ Western Sahara
○ Yemen
○ Zambia
○ Zimbabwe

[hh1_fname] [hh1_sname]: What is your ethnic group?

○ White - English/ Welsh/ Scottish/ Northern Irish/ British
○ White - Irish
○ White - Gypsy or Irish Traveller
○ Any other white background (please describe)
○ Asian/ Asian British - Indian
○ Asian/ Asian British - Pakistani
○ Asian/ Asian British - Bangladeshi
○ Asian/ Asian British - Chinese
○ Any other Asian/ Asian British background (please describe)
○ Black African
○ Black Caribbean
○ Any other Black/ African/ Caribbean background (please describe)
○ Arab
○ Any other ethnic group (please describe)
○ Mixed/ multiple ethnic groups - White and Black Caribbean
○ Mixed/ multiple ethnic groups - White and Black African
○ Mixed/ multiple ethnic groups - White and Asian
○ Any other mixed/ multiple ethnic background (please describe)
○ Prefer not to say

[hh1_fname] [hh1_sname]: Please describe your ethnic group:

_____

[hh1_fname] [hh1_sname]: Are you pregnant?

○ Yes
○ No

Confidential

What trimester of pregnancy are you in?	◯ Less than 12 Weeks ◯ 12 Weeks to 24 Weeks ◯ More than 24 weeks

Contact details

[hh1_fname] [hh1_sname]: What is your mobile phone number? This is so we can call you to make blood taking appointments and send your test results if you are selected for the swabbing part of the study. If you do not have a mobile phone, please enter your landline phone number, and we will seek alternative arrangements to send your results if you are selected for the swabbing part of the study.	_____

Address Line 1: This is to send you swabs (if you are chosen by the study team to partake in the swabbing study)	_____

Address Line 2:	_____

Address Line 3:	_____

Post Code:	_____

Confidential

Medical Background for [hh1_fname] [hh1_sname]

People's health can influence the severity of COVID illness, we want to find out more about this.

[hh1_fname] [hh1_sname]: Please provide your general practitioner's details:
This will allow us to link to your information to hospital records more accurately.

Name of Surgery:

_____

Address Line 1:

_____

Address Line 2:

_____

Address Line 3:

_____

Post Code:

_____

[hh1_fname] [hh1_sname] : Has a doctor or other health professional ever told you that you have any of the following conditions?
 Please select all that apply.

- ☐ Asthma
- ☐ Arthritis
- ☐ Congestive heart failure
- ☐ Coronary heart disease
- ☐ Angina
- ☐ Heart attack or myocardial infarction
- ☐ Stroke
- ☐ Emphysema
- ☐ Chronic bronchitis
- ☐ COPD (Chronic Obstructive Pulmonary Disease)
- ☐ Cystic fibrosis
- ☐ Hypothyroidism or an under-active thyroid
- ☐ Any kind of liver condition
- ☐ Cancer or malignancy
- ☐ Insulin treated diabetes
- ☐ Other diabetes
- ☐ Epilepsy
- ☐ High blood pressure/hypertension
- ☐ An emotional, nervous or psychiatric problem
- ☐ Multiple Sclerosis
- ☐ HIV
- ☐ Chronic kidney disease
- ☐ Conditions affecting the brain and nerves, such as Parkinson's disease, motor neurone disease, multiple sclerosis (MS), a learning disability or cerebral palsy
- ☐ Problems with your spleen or you've had your spleen removed
- ☐ Sickle cell disease
- ☐ Other long standing/chronic condition
- ☐ None of these

[hh1_fname] [hh1_sname]: Please specify:

_____

Confidential

[hh1_fname] [hh1_sname]: What type of cancer or malignancy was that? Please select all that apply	☐ Bowel/colorectal ☐ Lung ☐ Breast ☐ Prostate ☐ Liver ☐ Skin cancer or melanoma ☐ Blood or bone marrow cancer, such as leukaemia ☐ Other
[hh1_fname] [hh1_sname]: What type of cancer or malignancy was that? Please select all that apply	☐ Bowel/colorectal ☐ Lung ☐ Breast ☐ Liver ☐ Skin cancer or melanoma ☐ Blood or bone marrow cancer, such as leukaemia ☐ Other
[hh1_fname] [hh1_sname]: Has a doctor or other health professional ever told you that you have any of these conditions? Please select all that apply	☐ Asthma ☐ Cystic fibrosis ☐ Insulin treated diabetes ☐ Epilepsy ☐ Conditions affecting the brain and nerves, such as Parkinson's disease, motor neurone disease, multiple sclerosis (MS), a learning disability or cerebral palsy ☐ Sickle cell disease ☐ Other long standing/chronic condition ☐ None of these
[hh1_fname] [hh1_sname] : Have you received a letter from the NHS, saying that "the NHS has identified you as someone at risk of severe illness if you catch coronavirus, because you have an underlying disease or health condition that means if you catch the virus, you are more likely to be admitted to hospital than others"?	○ Yes ○ No
[hh1_fname] [hh1_sname] : Do you know your height and weight?	○ Yes ○ No
[hh1_fname] [hh1_sname]: Do you know your height in imperial (feet and inches) or metric (centimetres)? Please select the unit you prefer if you know both	○ Imperial (Feet and Inches) ○ Metric (centimetres)
[hh1_fname] [hh1_sname]: What is your height in centimetres (cm)? Please enter digits only, e.g. '5' and not 'five'	_____
[hh1_fname] [hh1_sname]: How many feet tall are you (rounded down)? Please enter the feet component of your height. For example if you're 5 foot 4, please enter 5	_____
[hh1_fname] [hh1_sname]: How many inches tall are you above your feet value? Please enter the inches component of your height. For example if you're 5 foot 4, please enter 4	_____

Confidential

[hh1_fname] [hh1_sname]: Do you know your weight in imperial (stone and pounds-lbs) or metric(kilograms)? Please select the unit you prefer if you know both	◯ Imperial (stone and pounds) ◯ Metric (kilograms)
[hh1_fname] [hh1_sname]: How much do you weigh in kilograms (kg)? Please enter digits only, e.g. '5' and not 'five'	_____
[hh1_fname] [hh1_sname]: What is your weight in stone, rounded down? For example if you are 8 stone, 10 pounds, please enter 8. If you do not use stone, please feel free to leave this blank and enter your weight fully in pounds	_____
[hh1_fname] [hh1_sname]: How much do you weight in pounds (lbs) (above your stone weight)? For example, if you are 8 stone, 10 pounds, please enter 10.If you did not enter a value for stone, please enter your weight fully in lbs here	_____

REDCap®

Confidential

[hh1_fname] [hh1_sname]: Referring to the illustration above, which body shape bests describes your body shape?

○ 1
○ 2
○ 3
○ 4
○ 5

HairSex hormones that affect male pattern baldness may also affect COVID severity

Confidential

[hh1_fname] [hh1_sname]: Referring to the illustration above, please select a number from 1-7 that best describes your hair	◯ 1 ◯ 2 ◯ 3 ◯ 4 ◯ 5 ◯ 6 ◯ 7

MedicationSome medicines may affect your risk of getting respiratory infections and may either protect against severe diseases or possibly increase the risk. We want to find out more about this

[hh1_fname] [hh1_sname] : Do you take any medication?	◯ Yes ◯ No

[hh1_fname] [hh1_sname]: Are you currently receiving treatment or taking medications that may affect your immune system? Please select all that apply	☐ Medication following an organ transplant ☐ Medicines such as steroid tablets that weaken the immune system ☐ Targeted therapy or chemotherapy for cancer treatment ☐ Radiotherapy for cancer treatment ☐ Other treatment or medication that may affect immune system ☐ None of these

[hh1_fname] [hh1_sname]: Do you regularly take medicine to surpress gastric acid? Please select all that apply	☐ Ranitidine (e.g. Zantac) ☐ Omeprazole (e.g. Losec) ☐ Antacids (e.g. Rennies) ☐ None of these

[hh1_fname] [hh1_sname]: Which of the following medicines do you take? Please select all that apply	☐ Regularly taking Aspirin ☐ Regularly taking "NSAIDS" e.g. Ibuprofen, nurofen, diclofenic, naproxen. ☐ Regularly taking blood pressure medicines ending in "-pril" such as enalapril, lisinopril, captopril, ramipril ☐ Regularly taking blood pressure measurements ending in "-sartan" such as losartan, valsartan, irbesartan ☐ Regularly taking anticoagulants e.g warfarin, ivaroxaban (Xarelto), dabigatran (Pradaxa), apixaban (Eliquis), edoxaban (Lixiana) ☐ Steroid tablets ☐ Regularly use a steroid inhaler ☐ Regularly take statins e.g. atorvastatin (Lipitor) ☐ None of these

[hh1_fname] [hh1_sname]: Which of the following medicines do you take? Please select all that apply	☐ Steroid tablets ☐ Regularly use a steroid inhaler

[hh1_fname] [hh1_sname]: Do you take any vitamin supplements? Please select all that apply	☐ Vitamin C Supplements ☐ Vitamin D Supplements ☐ Other ☐ None

[hh1_fname] [hh1_sname]: Have you ever had a flu vaccine?	◯ Yes ◯ No

Confidential

[hh1_fname] [hh1_sname]: Approximately when did you have your most recent flu vaccine?
If you do not remember the exact date, please select an approximate date

_____

Drinking and Smoking
Drinking and smoking affects the risk of many diseases. We want to find out if it affects the risk of COVID-19 infection

---

[hh1_fname] [hh1_sname]: Have you ever smoked cigarettes regularly?

○ Yes
○ No

[hh1_fname] [hh1_sname]: And do you smoke cigarettes at all nowadays?

○ Yes
○ No

[hh1_fname] [hh1_sname]: How many cigarettes do you smoke daily?
Please enter digits only, e.g. '5' and not 'five'

_____

[hh1_fname] [hh1_sname]: When did you give up smoking?

○ Less than 3 months ago
○ 3 - 6 months ago
○ More than 6 months ago but less than 1 year ago
○ 1 year or more ago

[hh1_fname] [hh1_sname]: Thinking about the past month, how often did you have a drink containing alcohol?

○ Daily
○ 4-6 Times per week
○ 2-3 Times per week
○ Weekly or Less
○ 2-4 times per month
○ Never

[hh1_fname] [hh1_sname]: How many drinks do you have on a typical day when you are drinking?

○ 1-2 Drinks
○ 3-4 Drinks
○ 5-6 Drinks
○ 7-9 Drinks
○ 10+

Accessing Health care during the lockdown

[hh1_fname] [hh1_sname]: Have you had any healthcare appointments cancelled, postponed or changed to a telephone or online (including video) consultation since the start of the pandemic?

○ Yes
○ No

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Confidential

Please tick all that applied	☐ I had an operation cancelled or postponed
	☐ I had a planned hospital admission cancelled or postponed
	☐ I had a hospital outpatient appointment cancelled or postponed
	☐ I had a hospital outpatient appointment changed to a phone call or online (including video) consultation
	☐ I had a GP appointment cancelled or postponed
	☐ I had a GP appointment changed to a phone call or online (including video) consultation
	☐ I had another NHS appointment cancelled or postponed
	☐ I had another NHS appointment changed to a phone call or online (including video)

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Confidential

Employment status for [hh1_fname] [hh1_sname]

Many people's work has been affected by the coronavirus and people's work can affect their chance of catching coronavirus. We'd like to know about your work and how it has been effected by the coronavirus.

[hh1_fname] [hh1_sname]: Thinking back to earlier this year, before the outbreak of the coronavirus pandemic. Which of these description best describes your work status?

- ◯ Employed full time
- ◯ Employed part time
- ◯ Self employed full time
- ◯ Self employed part time
- ◯ Retired
- ◯ Student
- ◯ Looking after house/family (not looking for work)
- ◯ Permanently sick or disabled
- ◯ Unemployed
- ◯ None of the above

[hh1_fname] [hh1_sname]: What is/was the name of your job?

_____

[hh1_fname] [hh1_sname]: Please describe what you do/did at work

_____

[hh1_fname] [hh1_sname]: Are you a health or social care worker?

- ◯ Yes
- ◯ No

What setting do you work in?

- ◯ Secondary Care
- ◯ Accident and emergency
- ◯ Primary Care
- ◯ Care home (residential or nursing)
- ◯ Community
- ◯ Other (specify)

Other (Please Specify)

_____

[hh1_fname] [hh1_sname]: Please select your healthcare profession

- ◯ Doctor
- ◯ Nurse
- ◯ Profession allied to medicine (e.g. occupational therapy, physiotherapy, podiatry)
- ◯ Psychological Professions
- ◯ Pharmacy
- ◯ Midwifery
- ◯ Healthcare science (e.g. laboratory, radiology)
- ◯ Management
- ◯ Porter
- ◯ Cleaner
- ◯ Administrative Staff with regular patient contact
- ◯ Administrative Staff with minimal or no patient contact
- ◯ Care Worker
- ◯ Personal Assistant
- ◯ Social Worker
- ◯ Community support and outreach worker
- ◯ Other

[hh1_fname] [hh1_sname]: Please specify

_____

Confidential

[hh1_fname] [hh1_sname]: What was your last job when you were working?

_____

[hh1_fname] [hh1_sname]: Are you a healthcare student?
e.g. medical student, student nurse

○ Yes
○ No

Employment during the pandemic

[hh1_fname] [hh1_sname]: BEFORE THE PANDEMIC, how many hours of paid work did you work per week?
Please enter digits only, e.g. '5' and not 'five'

_____

[hh1_fname] [hh1_sname]: SINCE THE PANDEMIC, during the months of March, April, May, how many hours of paid work have you worked since each week?
Please enter digits only, e.g. '5' and not 'five'

_____

It looks like you have reduced your paid work during the lockdown.

[hh1_fname] [hh1_sname] : Why have you had to reduce the number of hours?

○ Laid off by employer with certain recall date
○ Laid off or made redundant by employer with some prospect of recall
○ Employer cut hours
○ Have been put on furlough or paid leave
○ Using annual leave
○ On paid or statutory sick leave
○ On unpaid sick leave
○ Caring for children or others
○ Other reasons

[hh1_fname] [hh1_sname] : Why have you had to reduce the number of hours?

○ My business has been directly affected by regulations on opening or other new regulations
○ My business has been directly affected by limited supplies that I need for my business
○ My business has been directly affected by reduced demand for my services or products
○ Illness
○ Self-isolating
○ Caring for children or others
○ Other reasons

[hh1_fname] [hh1_sname]: Have you received a written letter from your employer informing you that you have been furloughed under the Coronavirus Job Retention scheme?

○ Yes
○ No

Working from home during the pandemic

[hh1_fname] [hh1_sname]: How often did you WORK FROM HOME during the following three time periods:

	(Nearly) Always	Often	Sometimes	(Almost) Never
Before the lockdown (before March 2020)	○	○	○	○

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Confidential

During the main lockdown (Mid March to Mid May) when we were asked to stay at Home, Save Lives, Support the NHS	○	○	○	○
After the easing of restrictions in mid-May, when we were encouraged to go back to work if we could not work from home (Stay Alert, Control the Virus, Save Lives)	○	○	○	○

[hh1_fname] [hh1_sname]: How do/did you usually travel to work?
Please choose one or more to represent a typical day

	Before the lockdown (before March 2020)	During the main lockdown (Mid March to Mid May) when we were asked to stay at Home, Save Lives, Support the NHS	After the easing of restrictions in mid-May, when we were encouraged to go back to work if we could not work from home (Stay Alert, Control the Virus, Save Lives)
By car or van	☐	☐	☐
Motorcycle, moped or scooter	☐	☐	☐
Taxi or minicab	☐	☐	☐
Train	☐	☐	☐
Underground	☐	☐	☐
Bus	☐	☐	☐
Tram or light railway	☐	☐	☐
Cycle	☐	☐	☐
Walk	☐	☐	☐
Other	☐	☐	☐
I did not travel to work during this period	☐	☐	☐

[hh1_fname] [hh1_sname]: BEFORE LOCKDOWN, how long did
it take to get to work each day?
Please provide the time for a one-way journey in   _____
minutes or enter 0 if you did not travel to work in
this period

[hh1_fname] [hh1_sname]: DURING LOCKDOWN, how long did
it take to get to work each day?
Please provide the time for a one-way journey in   _____
minutes or enter 0 if you did not travel to work in
this period

Confidential

[hh1_fname] [hh1_sname]: AFTER THE EASING OF RESTRICTIONS, how long did it take to get to work each day?
Please provide the time for a one-way journey in minutes or enter 0 if you did not travel to work in this period

_____

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Confidential

Finances details for [hh1_fname] [hh1_sname]

Many people have been affected financially by the coronavirus. We'd like to know how you have been affected and how you and your household are coping.

[hh1_fname] [hh1_sname]: What is your combined household income last year? We want to understand how COVID-19 impacts households with different levels of income	◯ 0-9,999 ◯ 10,000- 24,999 ◯ 25,000 - 49,999 ◯ 50,000 - 74,999 ◯ 75,000 - 99,999 ◯ 100,000 - 124,999 ◯ 125,000 - 149,999 ◯ 150,000 - 174,999 ◯ 175,000 - 199,999 ◯ 200,000 or more ◯ Prefer not to say
[hh1_fname] [hh1_sname] : BEFORE THE PANDEMIC, how would you say you were managing financially? Would you say you were:	◯ Living comfortably ◯ Doing alright ◯ Just about getting by ◯ Finding it quite difficult ◯ Finding it very difficult
[hh1_fname] [hh1_sname]: How would you say you are managing financially now? Would you say you were:	◯ Living comfortably ◯ Doing alright ◯ Just about getting by ◯ Finding it quite difficult ◯ Finding it very difficult
[hh1_fname] [hh1_sname]: BEFORE THE PANDEMIC, have you ever needed to use a food bank?	◯ Never ◯ Less than once a week ◯ Once a week or more
[hh1_fname] [hh1_sname]: SINCE THE PANDEMIC, have you needed to use a food bank?	◯ Never ◯ Less than once a week ◯ Once a week or more

Confidential

Caring information during the lockdown - [hh1_fname] [hh1_sname]

[hh1_fname] [hh1_sname]: About how many hours a week did you spend on childcare or home-schooling during the lockdown?
Please enter digits only, e.g. '5' and not 'five'

_____

[hh1_fname] [hh1_sname]: Who is mainly responsible for looking after the children or home schooling?

○ Mainly you
○ Mainly your husband/wife/partner
○ Jointly with your husband/wife/partner
○ Someone else

Confidential

Previous COVID-19 like illness for [hh1_fname] [hh1_sname]

[hh1_fname] [hh1_sname]: Have you EVER come into contact with anyone that was known or presumed to have COVID-19?
Close contact includes:
Physical contact with another personA five minute conversation with someone less than 2 metres awayBeing less than 2 metres away from someone for 15 minutes or more, even if you didn't talk to each otherPlease select all that apply.

☐ No
☐ Yes (a household member)
☐ Yes (at work)
☐ Yes (a non-household friend or relation)
☐ Yes (in public)
☐ Yes (other)
☐ Don't know

Did this person have COVID confirmed by a laboratory test?

○ Yes
○ No
○ Don't know

[hh1_fname] [hh1_sname]: Have you had an illness involving Cough, or Fever, or Loss of sense of smell since the 1st of January 2020?

○ Yes
○ No

[hh1_fname] [hh1_sname]: Which month did the illness start and which symptoms did you have?
If you had more than one illness, you may select multiple start months

	Jan 2020	Feb 2020	Mar 2020	Apr 2020	May 2020	Jun 2020	Jul 2020	Aug 2020	Sep 2020	Oct 2020	Nov 2020	Dec 2020	Jan 2021	Feb 2021
Cough	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
Fever	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
Loss of sense of smell	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐

[hh1_fname] [hh1_sname]: COVID-19 can cause a wide range of symptoms. Have you had an illness that you think might have been COVID-19, or which was confirmed as COVID-19?

○ Yes
○ No

Please describe in your own words how did the illness started and what you did when you started to feel ill?

_____

Please describe in your own words, what symptoms developed and what did you do?

_____

Please describe in your own words, how long did your symptoms last and are any symptoms still there?

_____

[hh1_fname] [hh1_sname]: Have you ever had a nose or throat swab test for COVID-19?

○ Yes
○ No
○ Not Sure

What month was the swab taken and what was the result?
Please select all the months in which you took each test (if you took multiple) and their results

REDCap

Confidential

	The test was positive	The test was negative	The test was unclear	I haven't had the result
Jan 2020	○	○	○	○
Feb 2020	○	○	○	○
Mar 2020	○	○	○	○
Apr 2020	○	○	○	○
May 2020	○	○	○	○
Jun 2020	○	○	○	○
Jul 2020	○	○	○	○
Aug 2020	○	○	○	○
Sep 2020	○	○	○	○
Oct 2020	○	○	○	○
Nov 2020	○	○	○	○
Dec 2020	○	○	○	○
Jan 2021	○	○	○	○
Feb 2021	○	○	○	○

12/03/2021 1:10pm

projectredcap.org

REDCap

Confidential

Thank You

We want to know what questions you think are important so we can try to answer them with the help of tens of thousands of Virus Watch participants. Each month we will ask our participants to say what questions they would like to see answered.

[hh1_fname] [hh1_sname]: What questions would you like
Virus Watch to answer?

_____

As we come out of a very difficult and tragic period we want to know about your three main worries related to COVID-19 and the COVID-19 response.

[hh1_fname] [hh1_sname]: What are your three main worries about the COVID-19 pandemic?

1st most worrying aspect:

_____

2nd most worrying aspect:

_____

3rd most worrying aspect:

_____

Please click submit to continue

projectredcap.org

REDCap

Confidential

Weekly Survey

Welcome to the weekly followup survey

surveydate

_____

In Virus Watch we are interested in the following types of symptoms:
General symptoms (e.g. fevers, general muscle aches, headache, joint pain,extreme tiredness, trouble with daily activities around the house)Respiratory Symptoms (e.g. cough, shortness of breath, earache, sore throat, runny nose, blocked nose, sneezing, wheeze, loss or altered senses of smell or taste).Eyes (e.g. eye redness, eye pain,sticky eye, deterioration of eyesight)RashesDigestive symptoms (e.g. diarrhoea or loose stools, vomiting, nausea, abdominal pain)This survey is about symptoms in the week (Monday to Sunday) before you received the email with the survey link.

Download Symptom Diary

[Attachment: "Virus_Watch_Symptom_Diary.pdf"]

Have you or anyone in the household had any of these symptoms in the past week? Please continue to report weekly symptoms even if you believe them to be related to a recent vaccine you have had.	◯ Yes ◯ No
Did any household members receive a COVID-19 test result in the past week?	◯ Yes ◯ No
Has anyone in the household been advised to self-isolate in the past week?	◯ Yes ◯ No

Please indicate who received a result for a COVID-19 (swab or lateral flow) test in the past week: If you have had multiple tests this week please report any positive test dates OR your last negative test dates (if all were negative)

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]	☐
[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: What was the result of the COVID-19 test?	◯ Positive ◯ Negative ◯ Unclear
[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: When was the test taken?	_____
[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: When did you receive the test result?	_____
[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]	☐
[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]: What was the result of the COVID-19 test?	◯ Positive ◯ Negative ◯ Unclear
[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]: When was the test taken?	_____

projectredcap.org   REDCap®

Confidential

[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]: When did you receive the test result?	_____
[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]	☐
[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]: What was the result of the COVID-19 test?	○ Positive ○ Negative ○ Unclear
[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]: When was the test taken?	_____
[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]: When did you receive the test result?	_____
[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]	☐
[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]: What was the result of the COVID-19 test?	○ Positive ○ Negative ○ Unclear
[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]: When was the test taken?	_____
[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]: When did you receive the test result?	_____
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]	☐
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]: What was the result of the COVID-19 test?	○ Positive ○ Negative ○ Unclear
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]: When was the test taken?	_____
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]: When did you receive the test result?	_____
[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]	☐
[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]: What was the result of the COVID-19 test?	○ Positive ○ Negative ○ Unclear
[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]: When was the test taken?	_____
[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]: When did you receive the test result?	_____

Please indicate who was advised to self isolate in the past week:

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]	☐

REDCap®

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Confidential

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Which of the following led to the request to self-isolate?

- ◯ The Test and Trace programme advised me to self-isolate because I have symptoms of COVID-19
- ◯ The Test and Trace programme advised me to self-isolate because I am had a positive test result
- ◯ The Test and Trace programme advised me to self isolate because I was in contact with a COVID-19 case
- ◯ The NHS COVID-19 app alerted me that I had been in contact with a COVID-19 case
- ◯ I have returned from a country where quarantine is advised after return.
- ◯ Other reason

[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]

☐

[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]: Which of the following led to the request to self-isolate?

- ◯ The Test and Trace programme advised me to self-isolate because I have symptoms of COVID-19
- ◯ The Test and Trace programme advised me to self-isolate because I am had a positive test result
- ◯ The Test and Trace programme advised me to self isolate because I was in contact with a COVID-19 case
- ◯ The NHS COVID-19 app alerted me that I had been in contact with a COVID-19 case
- ◯ I have returned from a country where quarantine is advised after return.
- ◯ Other reason

[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]

☐

[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]: Which of the following led to the request to self-isolate?

- ◯ The Test and Trace programme advised me to self-isolate because I have symptoms of COVID-19
- ◯ The Test and Trace programme advised me to self-isolate because I am had a positive test result
- ◯ The Test and Trace programme advised me to self isolate because I was in contact with a COVID-19 case
- ◯ The NHS COVID-19 app alerted me that I had been in contact with a COVID-19 case
- ◯ I have returned from a country where quarantine is advised after return.
- ◯ Other reason

[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]

☐

12/03/2021 1:10pm

projectredcap.org

REDCap®

Confidential

[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]: Which of the following led to the request to self-isolate?

○ The Test and Trace programme advised me to self-isolate because I have symptoms of COVID-19
○ The Test and Trace programme advised me to self-isolate because I am had a positive test result
○ The Test and Trace programme advised me to self isolate because I was in contact with a COVID-19 case
○ The NHS COVID-19 app alerted me that I had been in contact with a COVID-19 case
○ I have returned from a country where quarantine is advised after return.
○ Other reason

[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]

☐

[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]: Which of the following led to the request to self-isolate?

○ The Test and Trace programme advised me to self-isolate because I have symptoms of COVID-19
○ The Test and Trace programme advised me to self-isolate because I am had a positive test result
○ The Test and Trace programme advised me to self isolate because I was in contact with a COVID-19 case
○ The NHS COVID-19 app alerted me that I had been in contact with a COVID-19 case
○ I have returned from a country where quarantine is advised after return.
○ Other reason

[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]

☐

[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]: Which of the following led to the request to self-isolate?

○ The Test and Trace programme advised me to self-isolate because I have symptoms of COVID-19
○ The Test and Trace programme advised me to self-isolate because I am had a positive test result
○ The Test and Trace programme advised me to self isolate because I was in contact with a COVID-19 case
○ The NHS COVID-19 app alerted me that I had been in contact with a COVID-19 case
○ I have returned from a country where quarantine is advised after return.
○ Other reason

Please indicate who has had symptoms in the past week:

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]:

○ Yes, symptoms that have been present for less than 2 months
○ Yes, symptoms that developed after a COVID-19 like illness and have lasted for more than 2 months
○ Yes, symptoms that are part of a long term chronic illness
○ No symptoms

Confidential

[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]:	○ Yes, symptoms that have been present for less than 2 months ○ Yes, symptoms that developed after a COVID-19 like illness and have lasted for more than 2 months ○ Yes, symptoms that are part of a long term chronic illness ○ No symptoms
[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]:	○ Yes, symptoms that have been present for less than 2 months ○ Yes, symptoms that developed after a COVID-19 like illness and have lasted for more than 2 months ○ Yes, symptoms that are part of a long term chronic illness ○ No symptoms
[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]:	○ Yes, symptoms that have been present for less than 2 months ○ Yes, symptoms that developed after a COVID-19 like illness and have lasted for more than 2 months ○ Yes, symptoms that are part of a long term chronic illness ○ No symptoms
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]:	○ Yes, symptoms that have been present for less than 2 months ○ Yes, symptoms that developed after a COVID-19 like illness and have lasted for more than 2 months ○ Yes, symptoms that are part of a long term chronic illness ○ No symptoms
[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]:	○ Yes, symptoms that have been present for less than 2 months ○ Yes, symptoms that developed after a COVID-19 like illness and have lasted for more than 2 months ○ Yes, symptoms that are part of a long term chronic illness ○ No symptoms

Please indicate whether the following members have received a result for a COVID-19 (swab or lateral flow) test in the past week: If you have had multiple tests this week please report any positive test dates OR your last negative test dates (if all were negative)

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]:	☐
[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: What was the result of this test?	○ Positive ○ Negative ○ Unclear
[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: When was the test taken?	_____
[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: When did you receive the test result?	_____
[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]:	☐

projectredcap.org   REDCap

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Confidential

[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]: What was the result of this test?	◯ Positive ◯ Negative ◯ Unclear
[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]: When was the test taken?	_____
[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]: When did you receive the test result?	_____
[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]:	☐
[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]: What was the result of this test?	◯ Positive ◯ Negative ◯ Unclear
[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]: When was the test taken?	_____
[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]: When did you receive the test result?	_____
[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]:	☐
[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]: What was the result of this test?	◯ Positive ◯ Negative ◯ Unclear
[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]: When was the test taken?	_____
[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]: When did you receive the test result?	_____
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]:	☐
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]: What was the result of this test?	◯ Positive ◯ Negative ◯ Unclear
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]: When was the test taken?	_____
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]: When did you receive the test result?	_____
[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]:	☐
[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]: What was the result of this test?	◯ Positive ◯ Negative ◯ Unclear
[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]: When was the test taken?	_____

Confidential

[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]: When did you receive the test result?

_____

Please indiciate whether the following household members been advised to self-isolate in the past week:

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]

☐

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Which of the following led to the request to self-isolate?

◯ The Test and Trace programme advised me to self-isolate because I have symptoms of COVID-19
◯ The Test and Trace programme advised me to self-isolate because I am had a positive test result
◯ The Test and Trace programme advised me to self isolate because I was in contact with a COVID-19 case
◯ The NHS COVID-19 app alerted me that I had been in contact with a COVID-19 case
◯ I have returned from a country where quarantine is advised after return.
◯ Other reason

[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]

☐

[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]: Which of the following led to the request to self-isolate?

◯ The Test and Trace programme advised me to self-isolate because I have symptoms of COVID-19
◯ The Test and Trace programme advised me to self-isolate because I am had a positive test result
◯ The Test and Trace programme advised me to self isolate because I was in contact with a COVID-19 case
◯ The NHS COVID-19 app alerted me that I had been in contact with a COVID-19 case
◯ I have returned from a country where quarantine is advised after return.
◯ Other reason

[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]

☐

[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]: Which of the following led to the request to self-isolate?

◯ The Test and Trace programme advised me to self-isolate because I have symptoms of COVID-19
◯ The Test and Trace programme advised me to self-isolate because I am had a positive test result
◯ The Test and Trace programme advised me to self isolate because I was in contact with a COVID-19 case
◯ The NHS COVID-19 app alerted me that I had been in contact with a COVID-19 case
◯ I have returned from a country where quarantine is advised after return.
◯ Other reason

[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]

☐

REDCap

Confidential

[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]: Which of the following led to the request to self-isolate?	◯ The Test and Trace programme advised me to self-isolate because I have symptoms of COVID-19 ◯ The Test and Trace programme advised me to self-isolate because I am had a positive test result ◯ The Test and Trace programme advised me to self isolate because I was in contact with a COVID-19 case ◯ The NHS COVID-19 app alerted me that I had been in contact with a COVID-19 case ◯ I have returned from a country where quarantine is advised after return. ◯ Other reason
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]	☐
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]: Which of the following led to the request to self-isolate?	◯ The Test and Trace programme advised me to self-isolate because I have symptoms of COVID-19 ◯ The Test and Trace programme advised me to self-isolate because I am had a positive test result ◯ The Test and Trace programme advised me to self isolate because I was in contact with a COVID-19 case ◯ The NHS COVID-19 app alerted me that I had been in contact with a COVID-19 case ◯ I have returned from a country where quarantine is advised after return. ◯ Other reason
[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]	☐
[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]: Which of the following led to the request to self-isolate?	◯ The Test and Trace programme advised me to self-isolate because I have symptoms of COVID-19 ◯ The Test and Trace programme advised me to self-isolate because I am had a positive test result ◯ The Test and Trace programme advised me to self isolate because I was in contact with a COVID-19 case ◯ The NHS COVID-19 app alerted me that I had been in contact with a COVID-19 case ◯ I have returned from a country where quarantine is advised after return. ◯ Other reason

projectredcap.org

REDCap

Confidential

Vaccination	
Has anyone in the household received a COVID-19 vaccine in the past week?	◯ Yes ◯ No ◯ Unsure (e.g. as part of a blinded COVID-19 trial)
Please indicate who received a COVID-19 vaccine:	
[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]	☐
[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Please select which dose(s) of the COVID-19 vaccine you received?	☐ 1st Dose ☐ 2nd Dose
[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Which type of vaccine did you receive as the 1st dose?	◯ Pfizer Biontech vaccine ◯ Oxford AstraZeneca vaccine ◯ Other vaccine ◯ Don't know/Don't remember
[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: What date did you receive the 1st dose? (dd-mm-yyyy) Please provide an estimate if you cannot recall the date	_____
[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Which type of vaccine did you receive as the 2nd dose?	◯ Pfizer Biontech vaccine ◯ Oxford AstraZeneca vaccine ◯ Other vaccine ◯ Don't know/Don't remember
[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: What date did you receive the 2nd dose? (dd-mm-yyyy) Please provide an estimate if you cannot recall the date	_____
[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]	☐
[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]: Please select which dose(s) of the COVID-19 vaccine you received?	☐ 1st Dose ☐ 2nd Dose
[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]: Which type of vaccine did you receive as the 1st dose?	◯ Pfizer Biontech vaccine ◯ Oxford AstraZeneca vaccine ◯ Other vaccine ◯ Don't know/Don't remember
[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]: What date did you receive the 1st dose? (dd-mm-yyyy) Please provide an estimate if you cannot recall the date	_____

12/03/2021 1:10pm

projectredcap.org

REDCap

Confidential

[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]: Which type of vaccine did you receive as the 2nd dose?	◯ Pfizer Biontech vaccine ◯ Oxford AstraZeneca vaccine ◯ Other vaccine ◯ Don't know/Don't remember
[go_arm_1][hh2_fname] [go_arm_1][hh2_sname]: What date did you receive the 2nd dose? (dd-mm-yyyy) Please provide an estimate if you cannot recall the date	_____
[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]	☐
[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]: Please select which dose(s) of the COVID-19 vaccine you received?	☐ 1st Dose ☐ 2nd Dose
[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]: Which type of vaccine did you receive as the 1st dose?	◯ Pfizer Biontech vaccine ◯ Oxford AstraZeneca vaccine ◯ Other vaccine ◯ Don't know/Don't remember
[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]: What date did you receive the 1st dose? (dd-mm-yyyy) Please provide an estimate if you cannot recall the date	_____
[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]: Which type of vaccine did you receive as the 2nd dose?	◯ Pfizer Biontech vaccine ◯ Oxford AstraZeneca vaccine ◯ Other vaccine ◯ Don't know/Don't remember
[go_arm_1][hh3_fname] [go_arm_1][hh3_sname]: What date did you receive the 2nd dose? (dd-mm-yyyy) Please provide an estimate if you cannot recall the date	_____
[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]	☐
[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]: Please select which dose(s) of the COVID-19 vaccine you received?	☐ 1st Dose ☐ 2nd Dose
[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]: Which type of vaccine did you receive as the 1st dose?	◯ Pfizer Biontech vaccine ◯ Oxford AstraZeneca vaccine ◯ Other vaccine ◯ Don't know/Don't remember
[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]: What date did you receive the 1st dose? (dd-mm-yyyy) Please provide an estimate if you cannot recall the date	_____

REDCap®

Confidential

[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]: Which type of vaccine did you receive as the 2nd dose?	◯ Pfizer Biontech vaccine ◯ Oxford AstraZeneca vaccine ◯ Other vaccine ◯ Don't know/Don't remember
[go_arm_1][hh4_fname] [go_arm_1][hh4_sname]: What date did you receive the 2nd dose? (dd-mm-yyyy) Please provide an estimate if you cannot recall the date	_____
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]	☐
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]: Please select which dose(s) of the COVID-19 vaccine you received?	☐ 1st Dose ☐ 2nd Dose
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]: Which type of vaccine did you receive as the 1st dose?	◯ Pfizer Biontech vaccine ◯ Oxford AstraZeneca vaccine ◯ Other vaccine ◯ Don't know/Don't remember
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]: What date did you receive the 1st dose? (dd-mm-yyyy) Please provide an estimate if you cannot recall the date	_____
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]: Which type of vaccine did you receive as the 2nd dose?	◯ Pfizer Biontech vaccine ◯ Oxford AstraZeneca vaccine ◯ Other vaccine ◯ Don't know/Don't remember
[go_arm_1][hh5_fname] [go_arm_1][hh5_sname]: What date did you receive the 2nd dose? (dd-mm-yyyy) Please provide an estimate if you cannot recall the date	_____
[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]	☐
[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]: Please select which dose(s) of the COVID-19 vaccine you received?	☐ 1st Dose ☐ 2nd Dose
[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]: Which type of vaccine did you receive as the 1st dose?	◯ Pfizer Biontech vaccine ◯ Oxford AstraZeneca vaccine ◯ Other vaccine ◯ Don't know/Don't remember
[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]: What date did you receive the 1st dose? (dd-mm-yyyy) Please provide an estimate if you cannot recall the date	_____

REDCap®

Confidential

[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]: Which type of vaccine did you receive as the 2nd dose?	◯ Pfizer Biontech vaccine ◯ Oxford AstraZeneca vaccine ◯ Other vaccine ◯ Don't know/Don't remember

[go_arm_1][hh6_fname] [go_arm_1][hh6_sname]: What date did you receive the 2nd dose? (dd-mm-yyyy)

Please provide an estimate if you cannot recall the date

_____

Thank you for letting us know that someone in your household has been ill. We hope they feel better soon. Please always follow NHS and Public Health advice when someone is ill. We will always have a link to the latest COVID-19 advice on the Virus Watch Website.

If anyone has new symptoms to report, the following survey will ask about any illness and related health care as well as asking about isolation, time off work, measures to help stop infections spreading and activities that household members have done in the last week.

The survey usually takes about 10 minutes to complete for each member of the household who has been ill.

Thank you for completing the survey - we will be in touch again next week.

REDCap®

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Wkhh1

Symptoms - [go_arm_1][hh1_fname] [go_arm_1][hh1_sname]

The following sections are about the symptoms, use of treatments and access of medical services in the past week (the Monday-Sunday before you received the email with this survey link).

[go_arm_1][hh1_fname]: What parts of the body did your symptoms affect?
Select all that apply

- ☐ General symptoms (fevers, general muscle aches, headache, joint pain,extreme tiredness, trouble with daily activities around the house)
- ☐ Respiratory Symptoms (e.g. cough, shortness of breath, earache, sore throat, runny nose, blocked nose, sneezing, wheeze, loss or altered senses of smell or taste)
- ☐ Eyes (e.g. eye redness, eye pain, sticky eye, deterioration of eyesight)
- ☐ Rash
- ☐ Digestive symptoms (e.g. diarrhoea or loose stools, vomiting, nausea, abdominal pain)

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Which days did you have symptoms?
Please check all days that you had any of the above symptoms.

- ☐ Monday
- ☐ Tuesday
- ☐ Wednesday
- ☐ Thursday
- ☐ Friday
- ☐ Saturday
- ☐ Sunday

12/03/2021 1:10pm

projectredcap.org

REDCap

Confidential

General symptoms - [go_arm_1][hh1_fname] [go_arm_1][hh1_sname]

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Which of these general symptoms did you have?
Select all that apply

☐ Fever
☐ Feeling Feverish
☐ Chills and shakes
☐ Night Sweats
☐ Muscle Aches
☐ Bone or Joint Aches
☐ Loss of Appetite
☐ Headache
☐ Lack of concentration
☐ Lighheaded or dizzy
☐ Not sleeping
☐ Fatigue / Feeling unusually tired
☐ Difficulty with daily activities around the house
☐ Needed extra time in bed
☐ Could not get out of bed
☐ Confusion, disorientation, or hallucinations (altered mental state)
☐ None of these symptoms

Please identify how severe your symptoms were

Fever

	Less than 37.8 C (100.0 F)	37.8-38.9 C (100-102 F)	39-39.9 C (102-103.9 F)	40 C (104 F) or more	Did not take temperature Don't remember
Monday	○	○	○	○	○
Tuesday	○	○	○	○	○
Wednesday	○	○	○	○	○
Thursday	○	○	○	○	○
Friday	○	○	○	○	○
Saturday	○	○	○	○	○
Sunday	○	○	○	○	○

Feeling Feverish

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Chills and Shakes

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Confidential

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Night Sweats

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Muscle Ache

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Bone or Joint ache

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Loss of Appetite

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Confidential

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Headache

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Confusion, disorientation, or hallucinations (altered mental state)

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Lack of Concentration

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Lightheaded or Dizzy

Confidential

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Not Sleeping

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Fatigue/Feeling Unusually Tired

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Difficulties with Daily Activities

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Needed extra time in bed

Confidential

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Could not get out of bed

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

12/03/2021 1:10pm

projectredcap.org

REDCap

Confidential

Respiratory Symptoms - [go_arm_1][hh1_fname] [go_arm_1][hh1_sname]

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Which
Respiratory symptoms did you have?
Select all that apply

- ☐ Runny Nose
- ☐ Blocked Nose
- ☐ Sinus pain / congestion
- ☐ Dry cough
- ☐ Coughing up Green Phlegm
- ☐ Coughing up White Phlegm
- ☐ Loss or change to sense of smell
- ☐ Loss or change to sense of taste
- ☐ Sneezing
- ☐ Sore Throat
- ☐ Swollen tonsils
- ☐ Swollen glands (enlarged lymph nodes)
- ☐ Ear pain or change in hearing
- ☐ Fluid leaking from ear
- ☐ Shortness of breath difficulty breathing
- ☐ Wheezing
- ☐ Chest pain (not changed by breathing or moving)
- ☐ Chest pain when breathing in
- ☐ None of these symptoms

Please identify how severe your symptoms were

Runny Nose

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Blocked Nose

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Sinus Pain/Congestion

	None	Mild	Moderate	Severe
Monday	○	○	○	○

Confidential

Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Dry cough

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Coughing up Green Phlegm

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Coughing up White Phlegm

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Loss or change to sense of smell

Confidential

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Loss or change to sense of taste

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Sneezing

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Sore Throat

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Swollen Tonsils

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Confidential

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Swollen Glands (enlarged lymph nodes)

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Ear pain or change in hearing

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Fluid leaking from ear

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Shortness of Breath/difficulty breathing

Confidential

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Wheezing

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Chest pain (not changed by breathing or moving)

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Chest pain when breathing in

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Confidential

Other Symptoms - [go_arm_1][hh1_fname] [go_arm_1][hh1_sname]

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Which eye related symptoms did you have this week?
Select all that apply

- ☐ Eye redness
- ☐ Sticky Eye
- ☐ Eye pain
- ☐ Deterioration of eyesight
- ☐ None of these symptoms

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Where did the rash affect you?

- ☐ Rash (all over)
- ☐ Rash (local)
- ☐ None of these symptoms

Where on the body did the rash affect you?

_____

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Which gastrointestinal symptoms did you have?
Select all that apply

- ☐ Diarrhoea (even mild)
- ☐ Vomiting (being sick)
- ☐ Nausea (feeling sick)
- ☐ Abdominal pain (not including menstrual pain)
- ☐ None of these symptoms

Please identify how severe your symptoms were

Red Eye(s)

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Sticky Eye(s)

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Eye Pain

Confidential

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Deterioration of eyesight

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Rash - All Over

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Rash - Local

	None	Mild	Moderate	Severe
Monday	○	○	○	○
Tuesday	○	○	○	○
Wednesday	○	○	○	○
Thursday	○	○	○	○
Friday	○	○	○	○
Saturday	○	○	○	○
Sunday	○	○	○	○

Diarrhoea (even mild)

12/03/2021 1:10pm

projectredcap.org

REDCap

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Confidential

	None	Mild	Moderate	Severe
Monday	◯	◯	◯	◯
Tuesday	◯	◯	◯	◯
Wednesday	◯	◯	◯	◯
Thursday	◯	◯	◯	◯
Friday	◯	◯	◯	◯
Saturday	◯	◯	◯	◯
Sunday	◯	◯	◯	◯

Vomiting (being sick)

	None	Mild	Moderate	Severe
Monday	◯	◯	◯	◯
Tuesday	◯	◯	◯	◯
Wednesday	◯	◯	◯	◯
Thursday	◯	◯	◯	◯
Friday	◯	◯	◯	◯
Saturday	◯	◯	◯	◯
Sunday	◯	◯	◯	◯

Nausea (feeling sick)

	None	Mild	Moderate	Severe
Monday	◯	◯	◯	◯
Tuesday	◯	◯	◯	◯
Wednesday	◯	◯	◯	◯
Thursday	◯	◯	◯	◯
Friday	◯	◯	◯	◯
Saturday	◯	◯	◯	◯
Sunday	◯	◯	◯	◯

Abdominal pain (not including menstrual pain)

	None	Mild	Moderate	Severe
Monday	◯	◯	◯	◯
Tuesday	◯	◯	◯	◯
Wednesday	◯	◯	◯	◯
Thursday	◯	◯	◯	◯
Friday	◯	◯	◯	◯
Saturday	◯	◯	◯	◯
Sunday	◯	◯	◯	◯

Confidential

COVID-19 testing for [go_arm_1][hh1_fname] [go_arm_1][hh1_sname]

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Have you sought COVID-19 testing for this illness via the NHS, government or your employer?	○ Yes ○ No
[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: You said you tried to get tested for COVID-19 via the NHS, government or your employer for this illness. Did you get tested?	○ Yes ○ No
[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Why did you not get an NHS test for COVID-19?	○ I was advised the test was not needed ○ I am waiting for an NHS test kit to arrive by post ○ I could not get to a testing centre ○ I felt better so decided not to get tested ○ Other - please specify
Other (please specify):	_____
[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: How long was the gap between your symptoms starting and you having an NHS COVID-19 test?	○ Same day ○ Next day ○ 2 days later ○ 3 to 4 days later ○ 5 to 7 days later ○ More than a week
What was the result of that test?	○ Positive for COVID-19 ○ Negative for COVID-19 ○ The result was unclear ○ Still awaiting result
[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: How long was the gap between your symptoms starting and you getting the NHS test results?	○ Same day ○ Next day ○ 2 days later ○ 3 to 4 days later ○ 5 to 7 days later ○ More than a week

REDCap®

Confidential

Tracing - [go_arm_1][hh1_fname] [go_arm_1][hh1_sname]

If you had an illness that may be COVID-19 you should follow national advice on reporting this illness and seeking care. We will always have a link to the latest advice on the Virus Watch website.

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Have you reported your illness to any organisation other than Virus Watch?
Select all that apply

- ☐ I did not report my illness to any other organisation
- ☐ Yes to the NHS Contact tracing app
- ☐ Yes to Google/Android contact tracing app
- ☐ Yes to the NHS Test and Trace service
- ☐ Yes to my employer
- ☐ Yes to my GP
- ☐ Yes to the NHS 111 online coronavirus service
- ☐ Yes to the general NHS 111 service
- ☐ Other (please specify)

Other (please specify)

_____

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Why did you not report your illness?

- ☐ I did not think it was COVID-19
- ☐ I didn't feel ill enough to need help
- ☐ I didn't know where to report it
- ☐ I didn't know I was supposed to report it
- ☐ I didn't want to self isolate
- ☐ I didn't want my contacts to have to self isolate
- ☐ I didn't want others to know that I might have COVID-19

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: From the time two days before your illness started to now, have you had direct or close contact with anyone OTHER THAN HOUSEHOLD MEMBERS?

- ☐ Non-Household Direct Contacts - these are people you had direct physical contact with or with whom you exchanged at least a few words within a 2 metre distance (e.g. a handshake, embracing, kissing, contact sports).
- ☐ Non-Household Close contacts - these are people who were within 2 metres of you for 15 minutes or more but who you did not speak to or touch.
- ☐ I did not have direct or close contact with anybody other than household members

How many people did you have DIRECT CONTACT with other than household members?
Please enter digits only, e.g. '5' and not 'five'

_____

How many people did you have CLOSE CONTACT with other than household members?
Please enter digits only, e.g. '5' and not 'five'

_____

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Has anyone contacted you to ask about who you have been in contact with prior to or during your illness(contact tracing)?
Please select all that apply

- ☐ No
- ☐ Yes - my GP
- ☐ Yes - the NHS Test and Trace System
- ☐ Yes - telephone advisory service
- ☐ Yes - through an online form
- ☐ Yes - through an app
- ☐ Yes - through my employer
- ☐ Yes - through my place of education
- ☐ Yes - the local public team
- ☐ Other - please specify

Other please specify:

_____

Confidential

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Was anyone other than a household member asked to self-isolate because of contact with you?	◯ Yes - and I know how many were asked to self isolate ◯ Yes - but I don't know how many were asked to self isolate ◯ Nobody was asked to self isolate ◯ I don't know if anyone was asked to self isolate
How many people other than household contacts were asked to self-isolate because of contact with you? Please enter digits only, e.g. '5' and not 'five'	_____

Confidential

Health Advice / Consultation - [go_arm_1][hh1_fname] [go_arm_1][hh1_sname]

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: You should follow official national advice about what to do if you have symptoms of COVID-19. We will always include a link to the latest advice on the Virus Watch website.

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Did the illness lead you (or someone else on your behalf) to seek advice about your symptoms this week? This includes advice from: NHS 111 PharmaciesNurses or doctorsThe internetFriends and family	○ Yes ○ No

Where was the advice or information sought from?	☐ NHS 111 COVID-19 website ☐ NHS 111 COVID-19 phone line ☐ COVID-19 testing centre ☐ Internet (e.g. WebMD , NHS choices) ☐ Pharmacist ☐ GP (by phone) ☐ GP (visit to practice) ☐ GP (online (including video)) ☐ Walk-in centre ☐ A&E ☐ Hospital ☐ Friends or family ☐ Other (please specify)

Other (Please Specify):

_____

On which days was the medical advice or information sought from these sources Please check all that that apply on each day

	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
Internet (e.g. WebMD , NHS choices)	☐	☐	☐	☐	☐	☐	☐
NHS 111 COVID-19 phone line	☐	☐	☐	☐	☐	☐	☐
NHS 111 COVID-19 website	☐	☐	☐	☐	☐	☐	☐
Pharmacist	☐	☐	☐	☐	☐	☐	☐
GP (by phone)	☐	☐	☐	☐	☐	☐	☐
GP (visit to practice)	☐	☐	☐	☐	☐	☐	☐
GP (online (including video))	☐	☐	☐	☐	☐	☐	☐
Walk-in centre	☐	☐	☐	☐	☐	☐	☐
COVID-19 testing centre	☐	☐	☐	☐	☐	☐	☐
A&E	☐	☐	☐	☐	☐	☐	☐
Hospital	☐	☐	☐	☐	☐	☐	☐

REDCap®

Confidential

Medication - [go_arm_1][hh1_fname] [go_arm_1][hh1_sname]

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Did your symptoms lead to taking any medicines during the survey week?
This includes prescribed medicines, medicine brought at the chemist or shops, or vitamin supplements

○ Yes
○ No

On which days did you take the medicines:
Please select all that apply

	Mon	Tues	Wed	Thurs	Fri	Sat	Sun
Paracetamol	☐	☐	☐	☐	☐	☐	☐
Ibuprofen, nurofen, diclofenac, naproxen or other NSAID	☐	☐	☐	☐	☐	☐	☐
Aspirin	☐	☐	☐	☐	☐	☐	☐
Antibiotics	☐	☐	☐	☐	☐	☐	☐
Cold or flu remedies - over the counter	☐	☐	☐	☐	☐	☐	☐
Vitamin Supplements	☐	☐	☐	☐	☐	☐	☐
Other (please describe)	☐	☐	☐	☐	☐	☐	☐

Please specify:

_____

REDCap®

Confidential

Isolation and Infection Control - [go_arm_1][hh1_fname]

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: During the past week, on which days did you:

	Mon	Tues	Wed	Thurs	Fri	Sat	Sun	None
Leave the house/flat or garden	☐	☐	☐	☐	☐	☐	☐	☐
Wear a facemask or face covering outside the home	☐	☐	☐	☐	☐	☐	☐	☐
Sleep in a room with no one else in it?	☐	☐	☐	☐	☐	☐	☐	☐
Wear a face mask or face covering at home?	☐	☐	☐	☐	☐	☐	☐	☐
Have a meal with other members of your household?	☐	☐	☐	☐	☐	☐	☐	☐
Watch television with other members of your household?	☐	☐	☐	☐	☐	☐	☐	☐

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: During your illness, what best describes your approach to preventing spread of infection in the household?

○ I did not think my illness was COVID-19, so I did not take any special precautions
○ I thought it would spread whatever I did so did not take special precautions
○ I was worried about the illness spreading to others in the household so did what I could to stop this
○ None of the above

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Since your illness started, on which days did OTHER MEMBERS OF YOUR HOUSEHOLD:

	Mon	Tues	Wed	Thur	Fri	Sat	Sun	None
Wear a face mask or face covering when in the same room as you	☐	☐	☐	☐	☐	☐	☐	☐
Leave the house/flat or garden at all	☐	☐	☐	☐	☐	☐	☐	☐
Go to work	☐	☐	☐	☐	☐	☐	☐	☐
Wear a facemask or face covering outside the home	☐	☐	☐	☐	☐	☐	☐	☐

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: Why did other household members leave the house?
Please select all that apply

☐ They did not think my symptoms were related to COVID-19
☐ They did not think there was any need for people without symptoms to stay at home
☐ They needed to go out to earn money
☐ They needed to go out to an important meeting
☐ Other reason

12/03/2021 1:10pm

Confidential

During your illness, how frequently have you washed your hands thoroughly and regularly with soap and water	○ Not at all ○ 1 or 2 times a day ○ 3 or 4 times a day ○ 5 or 6 times a day ○ 7 or 8 times a day ○ 9 or 10 times a day ○ More than 10 times a day
During your illness, on average, how frequently have you (or someone else) disinfected surfaces you might touch? Such as door knobs or hard surfaces	○ Several times a day ○ Daily ○ Less than daily ○ Never

[go_arm_1][hh1_fname] [go_arm_1][hh1_sname]: During your illness, how frequently have you:

	Not applicable	Almost always	Most of the time	Sometimes	Rarely	Never
Washed your hands after blowing your nose, sneezing or coughing	○	○	○	○	○	○
Used tissues when sneezing or coughing	○	○	○	○	○	○
Put tissues in the bin immediately after use	○	○	○	○	○	○

projectredcap.org

REDCap®

Confidential

Thank You

Please click submit to continue